Regulations decried by industry weighed against importance of EU biomedical talent
Experts are divided on whether pharmaceutical companies will cut research and innovation investment in the EU and US over regulatory concerns.
Pharma giants warn that investment could shift due to new laws such as an EU plan to link regulatory protections for new treatments to the speed of their rollout. But Elizabeth Kuiper, an associate director at the European Policy Centre think tank, believes investment flight will be stemmed by the need for talented researchers.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.